Weight-loss pens: incretins, weight loss and clinical safety.

Weight-loss pens went viral because they seem simple: a weekly injection, less hunger, visible weight loss, and results that used to be hard to achieve with diet alone.

The science behind them is broader. Semaglutide, liraglutide and tirzepatide are approved medications for specific indications; retatrutide represents a molecule still in research. Together, they bring a larger field into view:

• incretin therapies that connect the gut, brain, pancreas, liver, adipose tissue, muscle, cardiovascular risk and eating behavior;
• different hormonal mechanisms, each with its own potency, dose, route of administration and regulatory status;
• a new clinical conversation about adiposity, glucose, liver, apnea, cardiovascular risk, muscle preservation and maintenance.

The term comes from the incretin effect: after food intake, the gut secretes hormones that boost insulin secretion in a glucose-dependent way and signal to the brain, stomach and other metabolic systems that nutrients have arrived. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) belong to this class and are hormonal peptides, named for their molecular structure; “hormone” describes their systemic signaling function.

Because they act on endocrine receptors, factors like dose, titration, indication, sourcing and clinical follow-up determine the balance between benefit and risk.

The class can be organized like this:

• GLP-1: increases satiety, reduces hunger, slows stomach emptying, and improves insulin secretion when glucose rises.
• GIP: takes part in the insulin response after a meal and in metabolic communication with adipose tissue and the nervous system.

Semaglutide is the active ingredient behind different products. Ozempic is the original, large-scale weekly injectable semaglutide, developed and positioned for type 2 diabetes, with cardiovascular and kidney benefit in specific populations with type 2 diabetes per the US label. Wegovy uses the same molecule via weekly injection, in a higher-dose program and clinical-regulatory design aimed at chronic weight management, maintenance, cardiometabolic risk and specific indications depending on the country. Rybelsus is the daily oral semaglutide, formulated with SNAC to allow gastric absorption, used while fasting and positioned mainly as an oral alternative for type 2 diabetes.

The main difference is this: the active ingredient can be the same, and the regulatory product can be different. Each brand has its own formulation, route of administration, dose, escalation program, clinical studies, target population and approved indication.

Tirzepatide is a dual GIP and GLP-1 agonist. The logic of Mounjaro and Zepbound is different from the Ozempic/Wegovy logic. Both contain tirzepatide in a weekly subcutaneous injectable formulation, with essentially equivalent dose presentations: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. In the US, Mounjaro is the brand anchored in type 2 diabetes; Zepbound uses the same molecule and dose range with a label geared toward weight reduction and maintenance and moderate to severe obstructive sleep apnea in adults with obesity.

In Brazil, the commercial/regulatory logic differs from the US: Anvisa approved a new indication for Mounjaro for chronic weight management, including weight loss and maintenance, in adults with BMI greater than or equal to 30 kg/m2 or BMI greater than or equal to 27 kg/m2 with a weight-related comorbidity. So the distinction between Mounjaro and Zepbound is less a difference in active ingredient or route of administration and more a regulatory, clinical and market segmentation of the same tirzepatide.

Liraglutide is a GLP-1 agonist, sold as Saxenda and Olire. In Brazil, both are labeled for obesity or overweight; in the US and EU, weight management is handled under the Saxenda brand. Other liraglutide formulations, like Victoza and Lirux, are used mainly for type 2 diabetes. Liraglutide also appears combined with insulin degludec in Xultophy.

Retatrutide is a triple agonist of GIP, GLP-1 and glucagon, developed under the code LY3437943. It remains an investigational therapy, without an approved brand name and without regulatory registration in Brazil, the US or the EU. Even so, it already comes up in clinical discussions because it adds action on the glucagon receptor to the GIP/GLP-1 axis, aiming for greater energy expenditure, greater fat mobilization and more intense weight loss in studies.

Among the other medications in the class used mainly for type 2 diabetes are dulaglutide (Trulicity) and lixisenatide combined with insulin glargine (Soliqua). All of them belong to the incretin conversation, with indication, dose and clinical goals defined according to each product’s label.

Among the molecules still in study or under regulatory review are also the combination of cagrilintide + semaglutide (CagriSema) and new oral formulations. CagriSema remains an investigational therapy for obesity. Orforglipron is an oral GLP-1 agonist, outside the injectable-pen paradigm, and was approved by the FDA in 2026 as Foundayo for weight management in the US. Oral semaglutide for weight management received a positive recommendation from the EMA in 2026, with a European decision still pending; in the US, the Wegovy label already includes the tablet form.

Active ingredient	Classification	Clinical use/status	Administration	Mechanism of action	Regulatory authorization
Liraglutide (Saxenda, Olire, Victoza, Lirux, Xultophy)	GLP-1 receptor agonist, glucagon-like peptide 1	Weight management; type 2 diabetes in other formulations, depending on product, dose and local registration	Daily injection	Activates the GLP-1 receptor; increases glucose-dependent insulin secretion, reduces glucagon, increases satiety and slows gastric emptying	Brazil, US and EU for weight management; Brazil, US and EU for type 2 diabetes under specific brands
Semaglutide (Ozempic, Wegovy, Poviztra, Extensior, Rybelsus)	GLP-1 receptor agonist, glucagon-like peptide 1	Type 2 diabetes, weight management, cardiovascular risk reduction in eligible adults and other indications depending on formulation	Weekly injection; daily oral in specific formulations	Selectively activates the GLP-1 receptor; regulates appetite and caloric intake, reduces glucagon, increases glucose-dependent insulin and improves glycemic control	Ozempic and Rybelsus: type 2 diabetes/cardiorenal axis per label; Wegovy and Poviztra: weight management and cardiometabolic risk axis depending on country and indication
Tirzepatide (Mounjaro, Zepbound)	Dual GIP/GLP-1 agonist, glucose-dependent insulinotropic polypeptide + glucagon-like peptide 1	Weight management, type 2 diabetes and obstructive sleep apnea per US indication, depending on product and local registration	Weekly injection	Activates the GIP and GLP-1 receptors; improves glycemic control, increases satiety, reduces food intake and may amplify the effect on weight and metabolism	Brazil and EU for type 2 diabetes and weight management; US for weight management and obstructive sleep apnea as Zepbound and type 2 diabetes as Mounjaro
Retatrutide (no approved brand name)	Triple GIP/GLP-1/glucagon agonist	Obesity, under investigation; not yet a component of an FDA-approved medication and not considered safe and effective for any condition by the agency	Weekly injection in studies	Activates three receptors: GIP, GLP-1 and glucagon; combines satiety and insulin signaling with a glucagonergic component studied for weight loss, energy expenditure and metabolic effects	Under study; no regulatory approval in Brazil, the US or the EU
Dulaglutide (Trulicity)	GLP-1 receptor agonist	Type 2 diabetes	Weekly injection	Activates the GLP-1 receptor, with an effect on glucose-dependent insulin secretion, glucagon and gastric emptying	Brazil, US and EU for type 2 diabetes
Lixisenatide + insulin glargine (Soliqua, Suliqua)	GLP-1 agonist combined with basal insulin	Type 2 diabetes	Daily injection	Combines GLP-1 activation with basal insulin replacement	Brazil, US and EU for type 2 diabetes, depending on local brand name
Liraglutide + insulin degludec (Xultophy)	GLP-1 agonist combined with basal insulin	Type 2 diabetes	Daily injection	Combines GLP-1 activation with basal insulin replacement	Brazil, US and EU for type 2 diabetes
Cagrilintide + semaglutide (CagriSema)	Amylin analog + GLP-1 receptor agonist	Obesity, under investigation	Weekly injection in studies	Combines amylin signaling with GLP-1 activation, aiming for greater satiety and weight loss	Under study; no final regulatory approval for obesity
Orforglipron (Foundayo)	Oral, small-molecule GLP-1 agonist	Weight management in the US; under review or unavailable in other markets	Daily oral	Activates the GLP-1 receptor orally, outside the injectable-pen paradigm	Approved by the FDA in the US in 2026; not registered in Brazil

Regulatory note. Clinical indications vary by jurisdiction and by the label in force. Products with the same active ingredient can have different indications depending on formulation, route of administration, dose, clinical studies submitted, population evaluated and the decision of the local regulatory agency.

Current medicine understands adiposity as a chronic, biological, multifactorial disease capable of increasing the risk of type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia, metabolic-associated steatotic liver disease, MASH, obstructive sleep apnea, osteoarthritis, heart failure with preserved ejection fraction and loss of function. Because of this, guidelines like WHO 2025, ABESO 2026, ADA 2026, AACE 2025, NICE 2025 and EASO 2026 frame treatment as comprehensive care: nutrition, physical activity, strength training, sleep, mental health, medications when indicated, surgery under specific criteria, and longitudinal follow-up.

The WHO’s special communication published in JAMA in 2025 organizes this reading in a practical way: GLP-1 enters as long-term treatment for obesity in adults, combined with intensive behavioral therapy, within care that is person-centered, respectful, inclusive and sustainable. The medication gains clinical power when it’s part of an integrated care ecosystem.

The documented benefits go beyond weight loss. The literature shows reductions in waist and visceral fat, improvement in glucose and insulin resistance, blood pressure, triglycerides, liver fat, apnea symptoms in specific contexts, quality of life, function, and cardiovascular risk in selected groups. The SELECT study, for example, showed a reduction in major cardiovascular events with semaglutide in people with overweight or obesity and established cardiovascular disease, without diabetes. The observational study by Xie et al. (2025), in Nature Medicine, broadens the conversation by mapping favorable signals and risks across multiple health domains, reinforcing the importance of pharmacovigilance and active follow-up.

Given these benefits, the clinical question has matured. The pen is a possible tool within a larger care framework: diet, exercise, sleep, emotional management, behavioral strategy and follow-up. ADA 2026 describes intermittent fasting and time-restricted eating as possible dietary strategies, with a loss of 3% to 8% in short studies, a result close to that of continuous caloric restriction. The difference is that fasting reorganizes timing and energy availability; pharmacological incretins amplify hormonal signals of satiety, digestion and metabolism.

Because of this, the higher-level conversation goes beyond “how much weight is lost?” The central question becomes: which health outcome do we want to improve, with which strategy, in which person, with what safety, and with what maintenance plan? Answering that requires looking at labs, symptoms, body composition, lean mass, protein intake, gastrointestinal effects, gallbladder, pancreas, glucose, medications in use, the pen’s sourcing, and the risk of regaining weight after stopping. The goal is metabolic benefit while preserving muscle, function and autonomy.

What weight-loss pens are

“Weight-loss pens” is the popular name for medications used to treat obesity, overweight with complications, and type 2 diabetes, according to medical indication and regulatory registration. The term became associated with injectable presentations, although the field already includes oral formulations under review or with specific approval. In practice, the word “weight-loss” describes the most visible effect; the clinical category is broader and involves hormonal signaling, glucose, adiposity, metabolic inflammation, cardiovascular risk and function.

The common thread is action on hormonal receptors that influence hunger, satiety, digestion, glucose and adiposity. The clinical result improves when the medication becomes part of a plan with adequate nutrition, protein, training, sleep, hydration, follow-up, realistic goals, and monitoring of the outcomes that matter for that person.

How incretins work

After a meal, the gut releases signals that help the body understand that nutrients have arrived. Incretins are part of that conversation. They influence the pancreas, brain, stomach, liver, adipose tissue and satiety circuits.

In practice, treatment with GLP-1 or GIP/GLP-1 can favor:

• greater satiety;
• less of an urge to eat;
• improved glycemic control;
• better coordination of the response between glucose, insulin and satiety;
• lower energy intake;
• reduced waist and visceral fat;
• improvement in some cardiometabolic markers;
• organization of clinical outcomes that can involve the liver, apnea, cardiovascular risk and function, depending on the molecule, the population studied, and the approved indication.

The most visible effect is weight. The most important effect is the whole picture: waist, glucose, blood pressure, lipids, liver, apnea, mobility, metabolic inflammation, function and cardiovascular risk.

What the evidence shows

The evidence has grown fast. Today we have randomized clinical trials, Cochrane reviews, NEJM studies, international guidelines, a recent Brazilian guideline, and 2026 updates focused on personalized pharmacotherapy. The current reading separates four levels: an indication approved on the label, benefit demonstrated in a specific population, an expanding research signal, and a hypothesis that still needs a clinical trial.

In 2026, three references help organize the current picture: the ADA published specific standards for the pharmacological treatment of obesity in adults, the EASO updated its medication management algorithm, and reviews in NEJM, Nature Medicine and Nature Reviews Drug Discovery consolidated the expansion of GLP-1, GIP/GLP-1 and upcoming molecules.

In STEP 1, published in NEJM in 2021, weekly semaglutide 2.4 mg combined with a lifestyle intervention reduced average weight by 14.9% over 68 weeks, versus 2.4% with placebo. More than 86% of treated participants achieved at least 5% weight loss.

In SURMOUNT-1, published in NEJM in 2022, weekly tirzepatide reduced average weight by 15.0%, 19.5% and 20.9% at the 5 mg, 10 mg and 15 mg doses, versus 3.1% with placebo, in adults with obesity or overweight with complications, without diabetes.

In SURMOUNT-5, published in NEJM in 2025, tirzepatide was compared directly with semaglutide in adults with obesity without diabetes. Over 72 weeks, the average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. Waist also decreased more with tirzepatide.

The 2025 Cochrane reviews reinforce this picture:

• semaglutide reduced weight compared to placebo with high-certainty evidence in the medium term;
• tirzepatide reduced weight substantially and maintained the effect in longer-term data;
• liraglutide showed benefit versus placebo, with a smaller average effect than the more recent weekly therapies.

The network meta-analysis published in Nature Medicine in 2025 adds a practical reading: semaglutide and tirzepatide are among the therapies with the greatest average effect on weight and waist, while benefits by complication vary. Semaglutide has robust cardiovascular evidence in SELECT; tirzepatide has relevant data in obstructive sleep apnea and MASH; the ideal choice depends on the clinical target.

This distinction is essential for responsible writing. Cardioprotection in secondary prevention, glycemic control in type 2 diabetes, adiposity reduction, improvement in NASH/MASH in studied contexts, and obstructive sleep apnea with a specific indication are clinical conversations with different degrees of evidence and regulatory approval. Neurology, systemic inflammation, infectious risk, respiratory outcomes and mental health, meanwhile, appear in observational maps or research reviews, like the study by Xie et al. (2025) and the review on GLP-1 in Parkinson’s. These findings help guide future science, pharmacovigilance and smarter clinical questions, while prescribing remains anchored in approved indication, studied population and individual evaluation.

On the liver axis, the reading needs to be precise. In biopsy-confirmed NASH, daily semaglutide 0.4 mg increased NASH resolution without worsening fibrosis (59% versus 17% with placebo) and reduced weight by 13% versus 1%. Fibrosis improvement, in this phase 2 trial, was 43% versus 33% and was not superior to placebo. In practice, liver fat and inflammation are important targets, and fibrosis still requires its own stratification.

Another data point changes the maintenance conversation. In studies that evaluated discontinuation, regain was frequent: after 52 weeks without treatment, there was an average recovery of 67% of the weight lost with semaglutide and 53% with tirzepatide. This explains why current guidelines treat obesity as a chronic disease and speak of long-term follow-up.

This difference between molecules matters. Treatment needs to consider efficacy, tolerability, availability, cost, clinical history, therapeutic goal, maintenance and safety.

Each molecule has its own profile

Liraglutide. It was one of the first GLP-1 therapies used widely in obesity and type 2 diabetes, depending on formulation. It’s given daily and has consistent evidence of weight loss versus placebo. Today it tends to appear as an option with a smaller average effect than semaglutide and tirzepatide.

Semaglutide. It’s a GLP-1 agonist given weekly in injectable formulations, with oral formulations in specific contexts. It has robust evidence in obesity, type 2 diabetes, cardiovascular risk, and some cardiometabolic complication contexts. In SELECT, semaglutide reduced major cardiovascular events in people with overweight or obesity and established cardiovascular disease, without diabetes. In biopsy-confirmed NASH, it showed improved NASH resolution without worsening fibrosis, while fibrosis requires its own follow-up.

Tirzepatide. It acts on GIP and GLP-1. In current studies, it shows the greatest average effect on weight loss. SURMOUNT-5 provided a direct comparison with semaglutide, showing a greater reduction in weight and waist over 72 weeks. The molecule also comes up in discussions of type 2 diabetes, obstructive sleep apnea in adults with obesity, and metabolic liver disease, always depending on the population studied, the approved indication, and medical evaluation.

Retatrutide, CagriSema and orforglipron. These fronts show where the field is heading: triple agonism, combination with amylin, and oral formulations. Retatrutide and CagriSema remain in research for obesity; orforglipron shifts part of the conversation to oral GLP-1 therapies. The clinical point is to track the progress without getting ahead of the promise.

The choice between molecules belongs to the medical consultation. The best medication is the one that makes sense for the right person, at the right time, with a clear goal, safe sourcing and the right monitoring.

Benefits beyond the scale

Treatment with incretins can improve parameters that the scale shows only partially. Because of this, success should be assessed by looking at body composition and clinical outcomes, not just the weekly weight number.

Outcomes worth tracking include:

• waist circumference;
• glucose, glycated hemoglobin and insulin resistance;
• blood pressure;
• triglycerides and atherogenic cholesterol;
• liver fat and MASLD/MASH markers;
• obstructive sleep apnea symptoms;
• functional capacity;
• body composition;
• quality of life;
• cardiovascular risk in specific groups;
• signs of tolerability and safety, especially gastrointestinal, biliary, pancreatic and nutritional.

That’s the conceptual shift: obesity is now treated as a disease based on adiposity and complications. The Lancet Diabetes & Endocrinology Commission distinguishes clinical obesity, when excess adiposity already compromises organ, tissue or daily-activity function, from pre-clinical obesity, when there’s excess adiposity with preserved function and increased risk. BMI helps with screening; precision medicine also looks at waist, visceral fat, diabetes, hypertension, dyslipidemia, liver, sleep, joint pain, function, family history and cardiovascular risk.

At the same time, the GLP-1 field has expanded beyond the scale because these receptors take part in broad physiological networks. Drucker’s review (2026) describes this landscape in diabetes, obesity and comorbidities; Xie et al. (2025) map favorable associations and risks across multiple domains; Helal et al. (2025) shows investigation in Parkinson’s. For the patient, the safe, premium message is: there is expanding scientific potential, and the clinical decision remains anchored in approved indication, population-specific evidence, safety and follow-up.

Muscle, protein and training

When treatment works well, weight can drop fast. That power requires an essential clinical question: what tissue is being lost?

Losing risk-related fat is desirable. Preserving muscle mass, strength, bone and autonomy is also part of the treatment. Skeletal muscle is a metabolic, secretory organ: during contraction, it releases myokines that communicate with adipose tissue, liver, pancreas, bone, brain and the immune system. Because of this, training is part of the metabolic intervention.

This point becomes even more important in older adults. In the population study by Benz et al. (2024), sarcopenia and sarcopenic obesity were associated with higher 10-year mortality. That finding reinforces a central goal: reduce risk-related adiposity while preserving strength, gait, stability, bone and independence.

Higher-quality weight loss combines:

• adjusted protein intake;
• nutrient-dense meals;
• fiber and vegetables;
• hydration;
• resistance training;
• walking or aerobic exercise;
• sleep;
• monitoring of gastrointestinal symptoms;
• body composition assessment when possible.

The advisory by Mozaffarian et al. (2025), published in AJCN, places nutrition and lifestyle at the center of GLP-1 treatment. ADA 2026 reinforces the same direction: during intentional weight loss, it’s worth monitoring adequate intake, preventing protein insufficiency and micronutrient deficiencies, and pairing protein with resistance training to preserve lean mass. The pen helps regulate hunger and satiety; the meal plan preserves tissue, micronutrients, microbiota, energy and function.

The 2026 joint EASO-EFAD-ECPO consensus broadens this guidance and proposes that success should also be monitored through diet quality, gastrointestinal tolerance, strength, the ability to perform daily activities, bone health, the relationship with food and psychological wellbeing. It recommends a stepped-care model: basic monitoring for most people and more intensive nutritional, psychological, functional or body-composition support when there is vulnerability, low intake, rapid or excessive weight loss, persistent symptoms, frailty or functional decline.

During active weight loss, the consensus suggests considering approximately 1.0 to 1.5 g of protein per kg of adjusted bodyweight per day, with a pragmatic minimum of 60 g per day, alongside at least 25 g of fibre and approximately 2.0 to 2.5 litres of fluid per day. These are not universal targets: they should be adapted to tolerance, usual diet, climate, physical activity, medications and conditions such as chronic kidney disease. The publication itself stresses that direct evidence for specific protein and exercise thresholds in people receiving incretin-based therapies remains limited.

Monitoring does not need to mean complex tests and technologies for everyone. Weight and waist circumference can be combined with questions about weakness, grip strength or a five-times sit-to-stand test, while bioimpedance or DXA can be reserved for situations in which they add clinical information. Persistent vomiting, inability to maintain hydration or nutrition, progressive symptoms and functional loss require clinical review. Decisions to increase, delay, reduce, pause or discontinue a dose should be shared and should consider benefits, physical and psychological risks, and the maintenance plan.

When appetite drops sharply, the priority shifts to the quality of intake: smaller, regular meals, protein spread through the day, vegetables, fiber, fluids, micronutrients and gastrointestinal tolerance. Eating less should go hand in hand with eating better.

On intermittent fasting, the comparison needs to be made carefully. ADA 2026 describes intermittent fasting and time-restricted eating as dietary strategies capable of producing a loss of 3% to 8% of initial weight in short studies, with results close to those of continuous caloric restriction. That’s a different axis from the incretins: fasting organizes the eating window and energy availability; GLP-1 and GIP/GLP-1 modulate hunger, satiety, gastric emptying and metabolic response. In clinical practice, the priority is to prevent an intense drop in appetite from turning into long involuntary gaps, too little protein, too little dietary variety and lean-mass loss.

Safety and sourcing

Weight-loss pens are medications. The safe path begins with medical evaluation, prescription, a regulated product, a trustworthy pharmacy and follow-up.

In Brazil, Anvisa strengthened controls on GLP-1 agonists with prescription retention, enforcement measures on import, compounding and irregular products, plus pharmacovigilance alerts for use outside approved indications. In 2026, the agency also approved a dosing update for semaglutide in Wegovy and Poviztra, allowing a maintenance dose of up to 7.2 mg per week in adults with obesity and insufficient clinical response at 2.4 mg, according to approved criteria. This point is essential because injectable medications require purity, potency, stability, sterility, cold chain and correct dose.

The safe path includes:

• an individualized medical prescription;
• purchase at a regulated pharmacy;
• checking registration, batch, expiration date and packaging;
• guidance on application, storage and dose escalation;
• a plan for gastrointestinal effects;
• a review of medications in use;
• glucose monitoring when there’s diabetes or use of insulin/sulfonylureas;
• monitoring of muscle mass, protein intake and function.

Products of uncertain origin, without registration, or outside health regulations expose a person to the wrong dose, contamination, loss of stability, therapeutic failure and adverse events. Safety begins before the first injection.

When they enter the clinical conversation

These medications can enter the conversation when there’s obesity, overweight with complications, type 2 diabetes, cardiometabolic risk, central adiposity, or weight-related complications. The indication considers the whole person.

In the consultation, the physician typically evaluates:

• weight, waist, body composition and progression;
• glucose, insulin, glycated hemoglobin and diabetes risk;
• blood pressure, lipids and cardiovascular risk;
• liver, gallbladder, pancreas and kidney;
• gastrointestinal symptoms;
• mental health, binge eating and hunger patterns;
• family history;
• pregnancy, breastfeeding and reproductive plans;
• medications in use;
• treatment goal and capacity for follow-up.

Some contexts call for special care: a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, biliary disease, gastroparesis, kidney disease with dehydration risk, scheduled surgery, diabetes with medications that cause hypoglycemia, pregnancy and breastfeeding.

This list exists to inform the consultation, organize safety, and choose well. The final decision belongs to the physician who knows the history, examines, follows up, and adjusts the treatment.

How to talk with your doctor

A good consultation about weight-loss pens starts with clear goals.

Useful questions:

• What clinical problem do we want to treat: weight, waist, diabetes, cardiovascular risk, liver, apnea, joint pain, function, or a combination?
• Which medication makes the most sense for my history?
• What tests do I need before starting?
• How will we monitor gastrointestinal effects?
• How do we protect muscle mass?
• What protein, training and hydration targets fit my case?
• How will the dose escalation work?
• What changes if I have surgery, travel, a planned pregnancy, or a new medication?
• What is the maintenance plan?

Treatment works best when patient and physician track health outcomes beyond weekly weight. Waist, strength, energy, sleep, glucose, blood pressure, adherence, symptoms and dietary quality tell the full story.

Conclusion

Weight-loss pens represent a real shift in the treatment of obesity. Semaglutide and tirzepatide have strong evidence, current guidelines, and a clinical impact that goes beyond the scale.

In practical terms, liraglutide remains relevant historically and clinically, with daily administration and a smaller average effect on weight loss. Semaglutide reduced weight versus placebo with robust evidence and has important cardiovascular data in SELECT. Tirzepatide showed a greater average reduction versus placebo and, in SURMOUNT-5, outperformed semaglutide on weight and waist.

Comparing medications needs to take into account population, dose, duration, adherence, discontinuations, presence of diabetes, complications, cost, tolerability and clinical goal. The best treatment is the one that improves metabolic health, preserves muscle and function, reduces risk, and fits into the real life of the person being followed.

The power of these medications requires safe sourcing, medical prescription, nutrition, protein, training, body composition monitoring, and a long-term plan. The goal is to treat risk-related adiposity safely, improve metabolic health, and build maintenance.